Company Overview and News

Lancor Holdings reports standalone net loss of Rs 4.90 crore in the March 2017 quarter

2017-05-31 indiainfoline
For the full year,net profit rose 83.45% to Rs 18.62 crore in the year ended March 2017 as against Rs 10.15 crore during the previous year ended March 2016. Sales declined 4.84% to Rs 78.61 crore in the year ended March 2017 as against Rs 82.61 crore during the previous year ended March 2016.

Lancor Holding provides update on scheme of amalgamation

2017-03-03 indiainfoline
Further, Lancor Holdings (Transferee) filed the aforesaid Court order through appropriate e-forms with the Registrar of Companies (ROC), Chennai on 28 February 2017.

Stocks in news: TCS, Tree House, Bharat Financial, Sunil Hitech

2016-12-28 moneycontrol
Stocks in news: TCS | Tree House | Bharat Financial | eClerx | Jagran Prakashan | Sunil Hitech | Religare | Lancor Holdings | Mandhana Retail Ventures | Asian Oilfield | Optiemus Infracom | Dhanuka Agritech | Akzo Nobel and Bombay Burmah Trading Corporation are stocks, which are in news today.

Realty stocks tank on Govt's black money crackdown

2016-11-09 indiainfoline
Fourteen realty stocks tumbled 2.74% to 22.48% at 11:17 IST on BSE as the sector is expected to feel the heat of the government's move to phase out the old Rs 500 and Rs 1000 notes.

Land deal may buoy Lancor Holdings

2016-05-05 thehindubusinessline
Lancor Holdings, in a post-market-hours disclosure on Thursday, informed the exchanges that it had signed an agreement for sale of 6.27 acres of land for a consideration of ₹57.316 crore. The company has received the total amount and executed a sale deed for 0.17 acres. In April 2015, it had informed the bourses of the acquisition of 6.44 acres at Potheri from L&T Urban Infrastructure for a residential project.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

23h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...